Zhenglei Xu1†Ximin Lin2†Haotian Zeng2†Xiaoxin Ma1
Ghulam Nabi3
Zain Ul Abidin4Luolin Wang1*Lisheng Wang1*- 1Department of Gastroenterology, Shenzhen People’s Hospital, The Second Clinical Medical College, The First Affiliated Hospital, Jinan University, Southern University of Science and Technology, Shenzhen, Guangdong, China
- 2The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China
- 3Institute of Nature Conservation, Polish Academy of Sciences, Krakow, Poland
- 4Department of Intensive Care Unit, Kabir Medical College, Peshawar, Pakistan
Adenocarcinomas are one of the most common histological types of gastric cancer. It has been ranked fifth among common cancers and is the third among death causing cancers worldwide. The high mortality rate among patients with gastric cancer is because of its silent evolution, genetic heterogeneity, high resistance to chemotherapy as well as unavailability of highly effective therapeutic strategy. Until now a number of several treatment strategies have been developed and are being practiced such as surgery, chemotherapy, radio therapy, and immunotherapy, however, further developments are required to improve the treatment responses and reduce the side effects. Therefore, novel personal therapeutic strategies based on immunological responses should be developed by targeting different check points and key immune players. Targeting macrophages and related molecular elements can be useful to achieve these goals. In this minireview, we discuss the available treatment options, molecular underpinnings and immunological regulations associated with gastric adenocarcinoma. We further describe the possible check points and immunological targets that can be used to develop novel therapeutic options.
Introduction
Gastrointestinal cancers of stomach, esophagus, colon, pancreas and liver are considered as the leading cause of cancer morbidity and mortality (Moehler et al., 2022). These cancers have caused 3.2 million deaths in 2020 due to lack of convenient and effective therapeutic options for patients with severe symptoms (León-Gonzalez et al., 2014; Ahmed and Othman, 2020; Moehler et al., 2022). Gastric adenocarcinoma is considered the 5th most common cancer type and ranked 3rd among high deaths causing cancers worldwide (Hudler, 2012; Moehler et al., 2022). It is most common in Asian populations, and prognosis and effectiveness of treatments depends on regional differences in disease progression and etiology (Ivey et al., 2022). The molecular and epidemiologic background of gastric cancers is unique. For example, intestinal gastric adenocarcinoma develops from chronic gastritis caused by Helicobacter pylori, resulting in intestinal metaplasia, atrophy, and intraepithelial neoplasia (dysplasia), ultimately leading to cancer (Yakirevich and Resnick, 2013).
The available treatments include chemotherapy, radiation and surgery, where radiation therapy can be applied before or after surgery. Moreover, radiation therapy is also used in combination with chemotherapy for enhanced sensitization of tumor (Phan et al., 2023). Gastrointestinal cancers treatment through immunotherapeutic options include vaccine therapies (dendritic cell-based vaccines, peptide, protein, whole tumor cells), adoptive T cell transfer cytokines (IL-10, GM-CSF interferon-γ, interleukin-2), and checkpoint inhibitors (CTLA-4, PD-1, PD-L1) (Phan et al., 2023). However, the most common treatment strategy for gastric adenocarcinoma is surgical resection (He et al., 2021; Phan et al., 2023). Even though adjuvant therapies have improved treatment responses, patients can still develop metastases and become resistant to treatment (Phan et al., 2023). Therefore, further work is needed to develop more effective therapeutic options and identify novel drug targets to improve treatment and survival (Figure 1).
FIGURE 1. This figure depicts some key features of gastric cancer subtypes based on molecular biology. Inset charts represent the distribution of molecular subtypes in gastric tumours obtained stomach. The molecular classification of gastric cancer indicates four prominent genomic subtypes (Genomically stable tumours, EBV-infected tumours; chromosomally unstable tumours, and Microsatellite instability (MSI) tumours. This figure was adopted from The Cancer Genome Atlas Research Network according to the rights and permissions statement of the publisher (Comprehensive molecular characterization of gastric adenocarcinoma., 2014). (CIN, chromosomal instability; EBV, Epstein-Barr virus; MSI, Microsatellite instability; GS, genomically stable).
Esophagogastric adenocarcinomas can be successfully treated with immunotherapy alone or in combination with chemotherapy, whether the tumor is epidermal growth factor receptor 2 (Her2) positive or negative (Moehler et al., 2022). Chemotherapy is typically recommended to reduce symptoms, control disease and prolong survival in patients with surgically unresectable gastric cancers. On the other hand, patients with tolerance to high toxicity are treated with fluoropyrimidine and platinum double with an additional chemotherapy (Cassetta and Pollard, 2018; Ivey et al., 2022). Despite the availability of these treatment options, the selection and efficacy of the treatment is challenging due to intra-tumoral heterogeneity mediated treatment resistance (Ivey et al., 2022).
Prominent treatment strategies in practice
Due to the lack of robust prognostic data for gastric adenocarcinoma, it is crucial to determine the stage using the current tumour-node-metastasis (TNM) model that incorporates biomarkers (Trout et al., 2022). To guide T and N staging, endoscopic ultrasonography (EUS) with or without fine-needle aspiration is mainly used. In addition to Computed Tomography (CT) or positron emission tomography (PET) imaging, (Spolverato et al., 2015), staging laparoscopy is the gold standard for diagnosing gastric adenocarcinoma. Further investigations are required to confirm whether polarized enhanced laparoscopy and 3D high-definition laparoscopy offer additional advantages over 2D laparoscopy (Trout et al., 2022).
Perioperative therapy
Multimodality approaches have been reported with better treatment outcomes in the case of gastric adenocarcinoma. In patients with localized adenocarcinoma, perioperative chemotherapy (three preoperative and three postoperative cycles of epirubicin plus cisplatin and 5-fluorouracil) plus surgery was reported to be a more favorable approach than surgery alone (Cunningham et al., 2006). As a standard-of-care approach, 5-fluorouracil plus cisplatin for two or 3 months prior to surgery and four or 5 months after surgery was determined to be an appropriate perioperative chemotherapy regimen (Cunningham et al., 2006; Slagter et al., 2018; Janjigian et al., 2021).
Chemoradiotherapy
In patients with resectable gastric adenocarcinoma, postoperative chemotherapy has a limited role (Slagter et al., 2018). There is an interest in combining radiotherapy with chemotherapy in the neoadjuvant cancer treatment (Slagter et al., 2018).
Endoscopic resection
Adenocarcinoma of the stomach in the early stages can be resected using endoscopic submucosal dissection (ESD), a technique pioneered in Japan (Ahmed and Othman, 2020). In most cases of superficial gastric adenocarcinoma, ESD is recommended as the treatment of choice. For larger tumours, including those with ulcerations, ESD is more effective than endoscopic mucosal resection (EMR), however, ESD also requires greater skill than EMR (Ahmed and Othman, 2020).
Surgery
A gastrectomy with circumferential and linear tumour-free margins is the main principle of the surgery. Tumor stage, histological subtype, and location determine how much surgical resection is possible (Spolverato et al., 2015; Moehler et al., 2022). Typically, proximal margins should be 5 cm, but they can be increased to 8 cm for diffuse type tumors. In comparison with a D2 dissection, surgeons prefer a D1 dissection because the risk of morbidities is perceived to be higher, and the survival outcomes are minimally improved. Studies have shown that higher mortality and morbidities are observed in the D2 group gastrectomy, because of the surgeon being naïve to pancreatic and splenic resections (Amin et al., 2017). Additionally, bursectomy has been shown to reduce the risk of peritoneal metastases by en-bloc resection of the post-gastric cavity lining, which might contain free cancer cells and/or micro-metastases. It can be used as an alternative surgical procedure, however, it does not provide a long-term post-surgery advantage (Amin et al., 2017; Janjigian et al., 2021).
Minimally invasive surgery
The laparoscopic approach to gastrectomy is the most popular minimally invasive method, which offers similar survival rates to open gastrectomy when performed by experienced surgeons. A laparoscopic approach has been shown to improve postoperative recovery times, decrease blood loss, shorten hospital stays, and improve general health. Still, a large level improvements are required for laparoscopic gastrectomy to replace surgical approaches (He et al., 2018). The use of robotics in gastrectomy has evolved as an essential component of surgical armamentarium, and its safety and efficacy have been well documented. The robot-assisted gastrectomy uses a high-definition 3D camera, which ensures stable and magnified views, as well as tremor reduction (He et al., 2018).
Endoscopic resection
In early-stage tumours, endoscopic resection can be a viable alternative to open surgery. A larger tumour can be removed with either an EMR or an ESD, which requires a higher level of surgical skill. It is important to consider the depth, diameter, histological grade, and ulcerative component of the tumour when determining whether endoscopic resection is feasible (Hirata et al., 2023).
Molecular and immunological interpretations in gastric adenocarcinoma
Unveiling the underlying molecular mechanisms is crucial to elucidate immune evasion, therapeutic efficacy, and progression/development of cancer (Moehler et al., 2022). Therefore, previous studies have largely reported the molecular profiling of gastric adenocarcinoma, which have indicated deregulation of distinct oncogenic pathways such as proliferation, Wnt–β-catenin (Figure 2), and NF-κB (Cristescu et al., 2015). In the case of primary gastric adenocarcinomas, the most comprehensive molecular characterization was provided by “The Cancer Genome Atlas (TCGA)” in 2014 (Cancer Genome Atlas Research Network, 2014). Based on integrative clustering analysis of data received from six molecular platforms “DNA methylation, somatic mutation profiles and copy number variations, microRNA sequencing, proteomics analyses, and gene expression,” the primary gastric adenocarcinomas were classified into four subtypes (Chromosomal instability, EBV-positive, GI, MSI) (Comprehensive molecular characterization of gastric adenocarcinoma., 2014). In another molecular profiling study, published by the Asian Cancer Research Group (ACRG), 300 primary gastric adenocarcinomas were classified into four subtypes (MSI subtype, mesenchymal-like subtype, TP53-inactive subtype and TP53-active subtype) (Cristescu et al., 2015). Previous studies based on meta-analysis of bulk expression data related to gastric adenocarcinomas have indicated that high proportions of CD8+ T cells and M1 macrophages were associated with a more favorable prognosis of intestinal gastric cancer (Zeng et al., 2019).
FIGURE 2. This figure shows Want signaling pathway, and the associated regulatory mechanisms. Negative or positive feedback mechanisms associated with Wnt signaling pathway depend on the interaction between different molecules, which determine the function and importance of this pathway in gastric adenocarcinoma. In this pathway, Wnt ligand is facilitated to bind to FZD-LRP5/6 complex, while the destruction complex is inhibited by dishevelled (DVL), which prevents the degradation of β-catenin. β-catenin is accumulated in the cytoplasm followed by translocation into the nucleus, thereby activating transcription factors (Figure 2). The negative regulators of the Wnt signaling pathway are RNF43 and LRP1B (A). In case of mutation of loss of function of RNF43 or LRP1B, Wnt signaling is increased (B). The figure was adopted from the article published by Holm et al. (Holm et al., 2023) following the rights and permissions statement from the licensing agency/publisher. (DC; destruction complex, RNF; Ring Finger Protein, LRP; lipoprotein receptor-related protein, TCF; T-cell factor, LEF; lymphoid enhancer factor, LGR; Leucine-rich repeat-containing G-protein-coupled receptor, APC/MCC; Familial Adenomatous Polyposis).
Molecular targets
Gastric adenocarcinomas possess a number of unique molecular features that can be targeted clinically. KRAS alterations occur in several gastric adenocarcinomas, where KRASG13D and KRASG12D are common mutations, which can be targeted. Pan-KRAS agents can be used to target KRAS amplifications mediated overexpression. Furthermore, overexpression of HER2 encoding gene ERBB2 can be targeted along with targeting mutations associated with deficiencies in DNA damage repair (Hirata et al., 2023). Earlier therapeutic attempts involving anti-EGFR or anti-VEGF antibodies were not effective, therefore, next-generation therapies based including, vaccines, antibody-drug conjugates, antibodies, and cell therapies can be used to treat gastric adenocarcinoma. In case of gastric adenocarcinoma, the frequently altering oncogene KRAS has been reported to be involved in development of tumor (Canon et al., 2019; Hirata et al., 2023), thus activated KRAS can be targeted in aforementioned cancer using the combination of SHP2 and MEK inhibitors. Overexpression of ERBB2 (encoding HER2) depends on stage of disease stage, subtype of tumour other relevant variables (Chung et al., 2021). HER2 can be targeted by FDA approved trastuzumab, monoclonal antibody in combination with chemotherapy in patients with advanced-stage HER2-positive gastric adenocarcinoma (Safran et al., 2022; Hirata et al., 2023). Several HER2-targeting therapeutic options in combination with immune checkpoint inhibitors have shown promising results such as, trastuzumab deruxtecan; antibody–drug conjugate consisting of a humanized, monoclonal, anti- HER2 antibody bound to a cytotoxic topoisomerase I inhibitor (Wheeler et al., 2021). Several potential inhibitors for alterations in expression of receptor tyrosine kinases and RAS–RAF or PI3K–AKT–mTOR signalling cascades are active in gastric adenocarcinoma. Genomic alterations in mTOR PI3KCA, and PTEN have been reported in gastric adenocarcinoma, such that PI3KCA and mTOR mutations are potential activating alterations, while PTEN (loss-of-function mutation) activates PI3K–mTOR signalling, which could be targeted using specific inhibitors (Mishra et al., 2021).
Targeting stem cell signalling pathways
Immune regulation is important in cancer progression and treatment (Zeng et al., 2019; Varadé et al., 2020). In this regard transcriptional coactivators (such as YAP1) of the highly conserved developmental pathway known as HIPPO signalling pathway are responsible for immunosuppression. In gastric adenocarcinomas, deregulation or genetic modification of HIPPO pathway components is common (Wu et al., 2018). This deregulation promotes nuclear localization and transcription factors binding to induce the transcription of anti-apoptotic genes. The resulting antiapoptotic proteins induce the development of cancer stem cell-like phenotypes and metastatic dissemination. Drug have been designed for targeting downstream effectors of the HIPPO signalling pathway (such as downstream transcription coactivators; YAP1 and TEAD) are currently in clinical trials (Ajani et al., 2021).
On the other hand, highly conserved Wnt signalling pathway is known to maintain adult tissue homeostasis and regulate embryonic development. Based on the observation genes associated with Wnt pathway are dysregulated in gastric adenocarcinomas, scientists have considered this pathway as a potential therapeutic target (Koushyar et al., 2020). Moreover, Notch 1/3 and Jagged 1/2 are upregulated in gastric adenocarcinoma, therefore, inhibiting their expression can be helpful in treating gastric adenocarcinoma. Although, preliminary evidence indicate that Hedgehog signalling pathways are deregulated in gastric adenocarcinomas (Koh et al., 2021); however, further investigations are required to confirm if targeting this pathway can be useful treatment option.
Macrophages modulate therapeutic efficacy
The immune function and phenotypes of macrophages vary significantly depending on the cellular communication with immune microenvironments. This macrophage polarization plays contribute to inflammation and disease in the aspects of differentiation, survival, and instigation. Chronic inflammation triggers the production of pro-inflammatory transcription factors, while cancer cells attract macrophages by releasing cytokines and chemokines (TNF-α and IL-6) (Crusz and Balkwill, 2015; Chen et al., 2023). Macrophages cause cancer progression in mutagenic microenvironment by releasing inflammatory mediators (IL-6, TNF, and IFN-γ), growth factors like EGF and Wnt, reactive oxygen species, reactive nitrogen species, and proteases (Cassetta and Pollard, 2018). Tumor-associated macrophages (TAM)-derived IL-17 and IL-23 are associated with colon cancer development and progression, thus can play role in progression of gastric adenocarcinoma (Malesci et al., 2017).
Gastric cancer patients with high pretreatment TAM levels lived longer after receiving postoperative chemotherapy based on 5-fluorouracil (FU). Similarly, pretreatment high macrophage density was linked with an improved prognosis in patients treated with 5-FU adjuvant therapy (Malesci et al., 2017). Several immunotherapy approaches have been developed for cancer including tumor vaccines, adoptive cellular immunotherapy, antibodies, immune checkpoint inhibitors (ICIs), and small-molecule inhibitors. Several checkpoints connected with macrophages and T cells, which can be targeted for tumor growth inhibition (Weiskopf et al., 2016). Within the tumor microenvironment, reprogramming of macrophages regulates phagocytes and antigen-presenting cells. Macrophage phagocytosis if inhibited by inhibitors can suppress the immune system, thereby improving effectiveness of immunotherapy for gastric adenocarcinoma. Moreover, treatment based on targeting macrophages has been found more effective such as CSF-1R blockade with PLX3397 improved the efficacy of adoptive cell therapy against gastric cancer (Mok et al., 2014). The reported diversity and unique properties of TAMs in tumors can lead to create tailored therapeutic strategies, however, more in-depth research work is needed to unveil the role of TAMs and the underlying regulatory mechanisms associated with effective anti-tumor targets. Targeting TAMs can reverse tumor progression and play role in immune suppression, therefore targeting TAM may be potentially innovative therapeutic strategy in future (Chen et al., 2023).
RNA N6-methyladenosine (m6A) modification
To overcome the complications associated with targeted therapy, chemotherapy and immunotherapy, it is important to identify diagnostic and prognostic markers, which can be used efficiently in gastric cancer (Brown et al., 2018; Moehler et al., 2022). In mammalian genes, one of the most abundant epitope transcriptome modifications is N6-methyladenosine, which is a methylation modification on the sixth N atom of adenine. This reversible modification results from the interaction among readers, writers, and erasers. Earlier studies have confirmed that N6-methyladenosine modification contribute to the progression of tumours as well as the treatment process (Du et al., 2022). We know that a series of improvements in immunotherapy, radiotherapy, chemotherapy, targeted therapy, photosensitive therapy, and minimally invasive surgery have increased the success rate of cancer treatment. Gastric adenocarcinoma treatment strategies should be improved because total mortality and drug resistance remain serious obstacles (Sun et al., 2023). In this regard m6A modification can be studied further as it has provided new hope for the treatment of different common cancers. In this regard, molecular docking-based techniques should be considered to determine immunotherapeutic targets. A potential target could also be the M6A modified RNA. Furthermore, m6A-related genes can serve not only as prognostic markers, but also as predictive markers of tumour occurrence, progression, and growth (Sun et al., 2023).
JAK-STAT PATHWAY as a drug target in gastric adenocarcinoma
The Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway are involved in communication between cells and exterior environment (Xue et al., 2023). Activation of JAK-STAT signaling through cytokines, growth factors, interferons, and other specific molecules drive a series of physiological and pathological processes, including proliferation, metabolism, immune response, inflammation, and malignancy (Shitara et al., 2020; Xue et al., 2023). This JAK-STAT pathway can be targeted to develop effective therapeutic options for gastric adenocarcinoma such as cytokine or receptor antibodies, JAK inhibitors, and STAT inhibitors (Xue et al., 2023). Upstream cytokines and receptors are pivotal for modulating the functions of the JAK-STAT signaling pathway. Drugs responsible for manipulation of cytokines and receptors (such as tocilizumab that inhibits IL-6) can inhibit JAK-STAT, thus can be tested for the treatment of gastric adenocarcinoma. Most STAT inhibitors function by restricting STAT phosphorylation, inhibiting SH2-mediated dimerization, or inducing STAT degradation (Deodhar et al., 2022). Napabucasin enhances the efficacy of Bcl-2 inhibitor by blocking STAT3 and inducing DNA damage, thereby eliminating the immunosuppressive functions of the suppressor cells. Therefore, napabucasin has been recently approved by the FDA for the treatment of gastric cancer (Bitsch et al., 2022).
Microsatellite instability in gastric cancer and the consequences for immune regulation and therapy
Mutations in the DNA mismatch repair (MMR genes), resulting from germline or somatic epi/genetic abnormalities, create the molecular phenotype called MSI, characterized by the accumulation of numerous mutations across the genome in the repetitive sequences (Velho et al., 2014). MSI occurs in approximately 15%–30% of gastric cancer cases (Pedrazzani et al., 2009). The MSI gastric cancer can occur sporadically, due to hereditary syndromes (e.g., Lynch syndrome), and exposure to H. pylori (Machado et al., 2009; Pedrazzani et al., 2009). The main mechanism by which MMR system failure occurs in MSI gastrointestinal cancers is genetic and epigenetic alterations at the MMR system effectors, namely, h-MLH1 and h-MSH2 (Peltomäki, 2001). In the progression of gastric carcinogenesis, members of the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways are mutated and activated. Several studied specifically described mutations in the mixed lineage kinase 3 (MLK3), PIK3CA, KRAS, and epithelial growth factor receptor EGFR (Velho et al., 2010; Corso et al., 2011); Mutations in genes responsible for maintaining genomic integrity (e.g., MRE11, hMSH3, BLM, hMSH6, RAD50, MED1, and ATR) and cell cycle regulation and apoptosis (e.g., APAF1, BCL10, TGFβ, CASPASE5, RIZ, RII, TCF4, IGFIIR, BAX, and FAS) have been linked with MSI gastric cancer (Hudler, 2012). When MMR proteins are functionally lost, the phenotype is highly mutated with many missense and frameshift mutations, affecting key tumor suppressor genes and oncogenes. In contrast to microsatellite stable tumors (MSS), MSI cancers exhibit a 100- to 1000-fold increase in mutation rates (Hudler, 2012; Dudley et al., 2016). Microsatellites are particularly susceptible to replication errors; their repetitive sequences can be used to identify an intact or defective MMR (Hudler, 2012).
A major biomarker used to predict the benefit of ICIs across cancer types is MSI (Kavun et al., 2023). In MSI colorectal cancer, strong lymphocytic activation and the shift to a tumor microenvironment restrain metastatic potential, leading to a strong response to immunotherapy (Greco et al., 2023). A neoplastic cell with an MMR defect overexpresses several immune checkpoint proteins, including programmed death-ligand 1(PD-L1) and programmed death-1 (PD-1), that can be pharmacologically targeted, allowing the revival of cytotoxic immune response against the tumor (Greco et al., 2023).
Based on available data, gastric cancer patients need to have their MSI status evaluated for an accurate assessment of their prognosis. Gastric cancer is still considered a challenging cancer, despite all the recent advances in treatment. There is a need to gain a deeper understanding of the molecular aspects of MSI gastric cancer in order to develop new diagnostic and prognostic tools, as well as identify new therapeutic strategies and targets to treat gastric cancer (Velho et al., 2014).
Conclusion
Gastric adenocarcinoma is one of the major healthcare burdens worldwide. It is needed to know the severity of symptoms and nature of progression for successful treatment options. For instance, endoscopic resection has gained high recognition and is known for improved outcomes in primary cancers or accidentally detected tumors. To develop novel personalized treatment options, it is necessary to understand the molecular biology and immunological regulations associated with gastric adenocarcinoma. Suitable postoperative treatment strategies for gastric adenocarcinoma can be personalized cancer vaccines, bispecific or trispecific antibodies, and antibody–drug conjugates. Considering the importance of immunological system, macrophages are crucial elements that can be considered or targeted for improved treatment outcomes. Investigating the detailed mechanisms based on the involvement of macrophages in progressions is important, as these macrophages are main triggering factors, and key regulators of immune system. Therefore, determining their unique properties in tumors can provide the groundwork for designing tailored therapeutic approaches. However, large-scale investigations are needed to unveil the role of essential molecules or signals in functional reprogramming of TAMs.
Author contributions
ZX, XL, and HZ conceived and drafted the manuscript. XM, GN, and ZA critically reviewed and substantially revised the manuscript. LuW and LiW supervised and supported the study. All authors contributed to the manuscript and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
APC/MCC, Familial adenomatous polyposis; CIN, Chromosomal instability; CT, Computed tomography; DC, Destruction complex; EBV, Epstein-Barr virus; EMR, Endoscopic mucosal resection; ESD, Endoscopic submucosal dissection; EUS, Endoscopic ultrasonography; GS, Genomically stable; ICIs, Immune checkpoint inhibitors; JAK, Janus kinase; LEF, Lymphoid enhancer factor; LGR, Leucine-rich repeat-containing G-protein-coupled receptor; LRP, Lipoprotein receptor-related protein; MAPK, Mitogen-activated protein kinase; MLK3, Mixed lineage kinase 3; MMR, Mismatch repair; MSI, Microsatellite instability; PD-1, Programmed death-1; PD-L1, Programmed death-ligand 1; PET, Positron emission tomography; PI3K, phosphatidylinositol 3-kinase; RNF, Ring finger protein; TAM, Tumor-associated macrophages; TCF, T-cell factor; TCGA, The cancer genome atlas; TNM, Tumour-node-metastasis.
References
Ahmed, Y., and Othman, M. (2020). EMR/ESD: techniques, complications, and evidence. Curr. Gastroenterol. Rep. 22, 39. doi:10.1007/s11894-020-00777-z
Ajani, J. A., Xu, Y., Huo, L., Wang, R., Li, Y., Wang, Y., et al. (2021). YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut 70, 55–66. doi:10.1136/gutjnl-2019-319748
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., et al. (2017). The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. Ca. Cancer J. Clin. 67, 93–99. doi:10.3322/caac.21388
Bitsch, R., Kurzay, A., Özbay Kurt, F., De La Torre, C., Lasser, S., Lepper, A., et al. (2022). STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. J. Immunother. cancer 10, e004384. doi:10.1136/jitc-2021-004384
Brown, Z. J., Heinrich, B., and Greten, T. F. (2018). Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat. Rev. Gastroenterol. Hepatol. 15, 536–554. doi:10.1038/s41575-018-0033-6
Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209. doi:10.1038/nature13480
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., et al. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217–223. doi:10.1038/s41586-019-1694-1
Cassetta, L., and Pollard, J. W. (2018). Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17, 887–904. doi:10.1038/nrd.2018.169
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., et al. (2023). Macrophages in immunoregulation and therapeutics. Signal Transduct. Target. Ther. 8, 207. doi:10.1038/s41392-023-01452-1
Chung, H. C., Bang, Y.-J., S Fuchs, C., Qin, S.-K., Satoh, T., Shitara, K., et al. (2021). First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 17, 491–501. doi:10.2217/fon-2020-0737
Corso, G., Velho, S., Paredes, J., Pedrazzani, C., Martins, D., Milanezi, F., et al. (2011). Oncogenic mutations in gastric cancer with microsatellite instability. Eur. J. Cancer 47, 443–451. doi:10.1016/j.ejca.2010.09.008
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., et al. (2015). Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449–456. doi:10.1038/nm.3850
Crusz, S. M., and Balkwill, F. R. (2015). Inflammation and cancer: advances and new agents. Nat. Rev. Clin. Oncol. 12, 584–596. doi:10.1038/nrclinonc.2015.105
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., et al. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11–20. doi:10.1056/NEJMoa055531
Deodhar, A., van der Heijde, D., Sieper, J., Van den Bosch, F., Maksymowych, W. P., Kim, T.-H., et al. (2022). Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. Arthritis Rheumatol. Hob. N.J.) 74, 70–80. doi:10.1002/art.41911
Du, M., Peng, Y., Li, Y., Sun, W., Zhu, H., Wu, J., et al. (2022). MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma. Cell death Discov. 8, 53. doi:10.1038/s41420-022-00844-6
Dudley, J. C., Lin, M.-T., Le, D. T., and Eshleman, J. R. (2016). Microsatellite instability as a biomarker for PD-1 blockade. Clin. cancer Res. Off. J. Am. Assoc. Cancer Res. 22, 813–820. doi:10.1158/1078-0432.CCR-15-1678
Greco, L., Rubbino, F., Dal Buono, A., and Laghi, L. (2023). Microsatellite instability and immune response: from microenvironment features to therapeutic actionability—lessons from colorectal cancer. Genes (Basel). 14, 1169. doi:10.3390/genes14061169
He, H., Li, H., Su, X., Li, Z., Yu, P., Huang, H., et al. (2018). Study on safety of laparoscopic total gastrectomy for clinical stage I gastric cancer: the protocol of the CLASS02-01 multicenter randomized controlled clinical trial. BMC Cancer 18, 944. doi:10.1186/s12885-018-4846-z
He, S., Xu, J., Liu, X., and Zhen, Y. (2021). Advances and challenges in the treatment of esophageal cancer. Acta Pharm. Sin. B 11, 3379–3392. doi:10.1016/j.apsb.2021.03.008
Hirata, Y., Noorani, A., Song, S., Wang, L., and Ajani, J. A. (2023). Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat. Rev. Clin. Oncol. 20, 453–469. doi:10.1038/s41571-023-00767-w
Holm, B., Barsuhn, S., Behrens, H.-M., Krüger, S., and Röcken, C. (2023). The tumor biological significance of RNF43 and LRP1B in gastric cancer is complex and context-dependent. Sci. Rep. 13, 3191. doi:10.1038/s41598-023-30294-8
Hudler, P. (2012). Genetic aspects of gastric cancer instability. ScientificWorldJournal 2012, 761909. doi:10.1100/2012/761909
Ivey, A., Pratt, H., and Boone, B. A. (2022). Molecular pathogenesis and emerging targets of gastric adenocarcinoma. J. Surg. Oncol. 125, 1079–1095. doi:10.1002/jso.26874
Janjigian, Y. Y., Kawazoe, A., Yañez, P., Li, N., Lonardi, S., Kolesnik, O., et al. (2021). The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727–730. doi:10.1038/s41586-021-04161-3
Kavun, A., Veselovsky, E., Lebedeva, A., Belova, E., Kuznetsova, O., Yakushina, V., et al. (2023). Microsatellite instability: a review of molecular epidemiology and implications for immune checkpoint inhibitor therapy. Cancers (Basel) 15, 2288. doi:10.3390/cancers15082288
Koh, V., Chakrabarti, J., Torvund, M., Steele, N., Hawkins, J. A., Ito, Y., et al. (2021). Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids. Cancer Lett. 518, 59–71. doi:10.1016/j.canlet.2021.06.007
Koushyar, S., Powell, A. G., Vincan, E., and Phesse, T. J. (2020). Targeting Wnt signaling for the treatment of gastric cancer. Int. J. Mol. Sci. 21, 3927. doi:10.3390/ijms21113927
León-Gonzalez, A. J., Acero, N., Muñoz-Mingarro, D., López-Lázaro, M., and Martín-Cordero, C. (2014). Cytotoxic activity of hirsutanone, a diarylheptanoid isolated from Alnus glutinosa leaves. Phytomedicine 21, 866–870. doi:10.1016/j.phymed.2014.01.008
Machado, A. M. D., Figueiredo, C., Touati, E., Máximo, V., Sousa, S., Michel, V., et al. (2009). Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin. cancer Res. Off. J. Am. Assoc. Cancer Res. 15, 2995–3002. doi:10.1158/1078-0432.CCR-08-2686
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., et al. (2017). Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. oncoimmunology 6, e1342918. doi:10.1080/2162402X.2017.1342918
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., and Garrett, J. T. (2021). PI3K inhibitors in cancer: clinical implications and adverse effects. Int. J. Mol. Sci. 22, 3464. doi:10.3390/ijms22073464
Moehler, M., Högner, A., Wagner, A. D., Obermannova, R., Alsina, M., Thuss-Patience, P., et al. (2022). Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. Eur. J. Cancer 176, 13–29. doi:10.1016/j.ejca.2022.08.023
Mok, S., Koya, R. C., Tsui, C., Xu, J., Robert, L., Wu, L., et al. (2014). Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 74, 153–161. doi:10.1158/0008-5472.CAN-13-1816
Pedrazzani, C., Corso, G., Velho, S., Leite, M., Pascale, V., Bettarini, F., et al. (2009). Evidence of tumor microsatellite instability in gastric cancer with familial aggregation. Fam. Cancer 8, 215–220. doi:10.1007/s10689-008-9231-7
Peltomäki, P. (2001). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum. Mol. Genet. 10, 735–740. doi:10.1093/hmg/10.7.735
Phan, T., Zhang, X. H., Rosen, S., and Melstrom, L. G. (2023). P38 kinase in gastrointestinal cancers. Cancer Gene Ther. doi:10.1038/s41417-023-00622-1
Safran, H. P., Winter, K., Ilson, D. H., Wigle, D., DiPetrillo, T., Haddock, M. G., et al. (2022). Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet. Oncol. 23, 259–269. doi:10.1016/S1470-2045(21)00718-X
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., et al. (2020). Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419–2430. doi:10.1056/NEJMoa2004413
Slagter, A. E., Jansen, E. P. M., van Laarhoven, H. W. M., van Sandick, J. W., van Grieken, N. C. T., Sikorska, K., et al. (2018). CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 18, 877. doi:10.1186/s12885-018-4770-2
Spolverato, G., Ejaz, A., Kim, Y., Squires, M. H., Poultsides, G. A., Fields, R. C., et al. (2015). Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. J. Am. Coll. Surg. 220, 48–56. doi:10.1016/j.jamcollsurg.2014.06.023
Sun, X., Fu, S., Yuan, X., Pu, X., Wang, R., Wang, X., et al. (2023). RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential. Cancer Gene Ther. doi:10.1038/s41417-023-00628-9
Trout, R. M., Gnanatheepam, E., Gado, A., Reik, C., Ramella-Roman, J. C., Hunter, M., et al. (2022). Polarization enhanced laparoscope for improved visualization of tissue structural changes associated with peritoneal cancer metastasis. Biomed. Opt. Express 13, 571–589. doi:10.1364/BOE.443926
Varadé, J., Magadán, S., and González-Fernández, Á. (2020). Human immunology and immunotherapy: main achievements and challenges. Cell. Mol. Immunol. 18, 805–828. doi:10.1038/s41423-020-00530-6
Velho, S., Corso, G., Oliveíra, C., and Seruca, R. (2010). KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers. Adv. Cancer Res. 109, 123–143. doi:10.1016/B978-0-12-380890-5.00004-1
Velho, S., Fernandes, M. S., Leite, M., Figueiredo, C., and Seruca, R. (2014). Causes and consequences of microsatellite instability in gastric carcinogenesis. World J. Gastroenterol. 20, 16433–16442. doi:10.3748/wjg.v20.i44.16433
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., et al. (2016). CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J. Clin. Invest. 126, 2610–2620. doi:10.1172/JCI81603
Wheeler, D. A., Takebe, N., Hinoue, T., Hoadley, K. A., Cardenas, M. F., Hamilton, A. M., et al. (2021). Molecular features of cancers exhibiting exceptional responses to treatment. Cancer Cell 39, 38–53.e7. doi:10.1016/j.ccell.2020.10.015
Wu, D.-M., Wang, S., Wen, X., Han, X.-R., Wang, Y.-J., Shen, M., et al. (2018). LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-3p in papillary thyroid carcinoma. Cell Death Dis. 9, 947. doi:10.1038/s41419-018-0975-1
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., et al. (2023). Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct. Target. Ther. 8, 204. doi:10.1038/s41392-023-01468-7
Yakirevich, E., and Resnick, M. B. (2013). Pathology of gastric cancer and its precursor lesions. Gastroenterol. Clin. North Am. 42, 261–284. doi:10.1016/j.gtc.2013.01.004
Keywords: adenocarcinomas, diagnosis, gastric cancer, biomarker, therapy
Citation: Xu Z, Lin X, Zeng H, Ma X, Nabi G, Abidin ZU, Wang L and Wang L (2023) Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery. Front. Genet. 14:1238248. doi: 10.3389/fgene.2023.1238248
Received: 11 June 2023; Accepted: 27 July 2023;
Published: 11 August 2023.
Edited by:
Bing-Rong Liu, First Affiliated Hospital of Zhengzhou University, ChinaReviewed by:
Jens Hahne, Institute of Cancer Research (ICR), United KingdomCopyright © 2023 Xu, Lin, Zeng, Ma, Nabi, Abidin, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Luolin Wang, luolin_wang@126.com; Lisheng Wang, wangls168@163.com
†These authors have contributed equally to this work